Pages that link to "Q44709390"
Jump to navigation
Jump to search
The following pages link to Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India (Q44709390):
Displaying 50 items.
- Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia (Q21132005) (← links)
- Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective (Q28073426) (← links)
- Advances in Development of New Treatment for Leishmaniasis (Q28082097) (← links)
- Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations (Q28088410) (← links)
- Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis (Q28271849) (← links)
- Clinical status of agents being developed for leishmaniasis (Q28279390) (← links)
- Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004 (Q28283745) (← links)
- Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent (Q28475431) (← links)
- Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India (Q28538265) (← links)
- Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial (Q28554069) (← links)
- Advances in leishmaniasis (Q29617229) (← links)
- Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). (Q30275257) (← links)
- Acute febrile disease with splenomegaly and pancytopenia. A 66-year-old Greek patient with a prosthetic mitral valve (Q33375444) (← links)
- Leishmaniasis: a review. (Q33777851) (← links)
- Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects (Q34328882) (← links)
- Treatment options for visceral leishmaniasis (Q34510966) (← links)
- Oral miltefosine for the treatment of Indian visceral leishmaniasis (Q34531203) (← links)
- Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide (Q35160905) (← links)
- Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children (Q35694752) (← links)
- In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci (Q35759108) (← links)
- Progress in the treatment of a neglected infectious disease: visceral leishmaniasis (Q35917392) (← links)
- Visceral leishmaniasis clinical management in endemic districts of India, Nepal, and bangladesh (Q35977662) (← links)
- Optimal dosing of miltefosine in children and adults with visceral leishmaniasis (Q36086339) (← links)
- Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent - A Systematic Literature Review (Q36094815) (← links)
- Miltefosine to treat leishmaniasis (Q36192769) (← links)
- Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India (Q36313497) (← links)
- Miltefosine: oral treatment of leishmaniasis (Q36441483) (← links)
- Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis (Q36558539) (← links)
- Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites (Q36576096) (← links)
- Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. (Q36645795) (← links)
- Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. (Q36803937) (← links)
- HIV, visceral leishmaniasis and Parkinsonism combined with diabetes mellitus and hyperuricaemia: A case report (Q36922035) (← links)
- Miltefosine: First Oral Drug for Treatment of Visceral Leishmaniasis (Q37043455) (← links)
- Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan (Q37145727) (← links)
- Treatment of leishmaniasis with miltefosine: 2008 status (Q37249719) (← links)
- Therapeutic options for visceral leishmaniasis (Q37333942) (← links)
- Drug delivery strategies for therapy of visceral leishmaniasis (Q37702257) (← links)
- Parasitic infections and myositis (Q37924643) (← links)
- Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? (Q38188571) (← links)
- New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment. (Q38537004) (← links)
- Cutaneous leishmaniasis: therapeutic strategies and future directions (Q38872459) (← links)
- Elimination of Kala-Azar from the Southeast Asia Region (Q39099665) (← links)
- An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis. (Q39156596) (← links)
- Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum (Q39156601) (← links)
- American cutaneous leishmaniasis in infancy and childhood (Q39336818) (← links)
- First case of typical Old World cutaneous leishmaniasis treated with miltefosine (Q39492098) (← links)
- The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil (Q39731039) (← links)
- Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases (Q43037902) (← links)
- Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health (Q43167558) (← links)
- Alterations on the growth and ultrastructure of Leishmania chagasi induced by squalene synthase inhibitors (Q45138723) (← links)